Teva JPM-2025_presentation_vF.pdf

1、January 13,202543rdAnnual J.P.Morgan Healthcare ConferenceTeva Pharmaceutical Industries Ltd.2|This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on managements current beliefs and expectations and are subj

2、ect to substantial risks and uncertainties,both known and unknown,that could cause our future results,performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.Important factors that could cause or contribute to such differences include ris

3、ks relating to:our ability to successfully compete in the marketplace,including:that we are substantially dependent on our generic products;concentration of our customer base and commercial alliances among our customers;delays in launches of new generic products;our ability to develop and commercial

4、ize biopharmaceutical products;competition for our innovative medicines;our ability to achieve expected results from investments in our product pipeline;our ability to develop and commercialize additional pharmaceutical products;our ability to continue to successfully execute our Pivot to Growth str

5、ategy,including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio,whether organically or through business development,and to sustain and focus our portfolio of generics medicines;and the effectiveness of our pate

6、nts and other measures to protect our intellectual property rights,including any potential challenges toour Orange Book patent listings in the U.S.;our substantial indebtedness,which may limit our ability to incur additional indebtedness,engage in additional transactions or make new investments,may